¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"early receptor potential"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • corpuscular receptor
    ¼Òü¼ö¿ëü
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • distance receptor
    ¿ø°Ý¼ö¿ë±â
  • dominant receptor
    ¿ì¼º¼ö¿ëü
  • estrogen receptor
    ¿¡½ºÆ®·Î°Õ¼ö¿ëü
  • free receptor
    À¯¸®¼ö¿ëü
  • gustatory receptor
    ¹Ì°¢¼ö¿ë±â
  • H1 receptor
    H1¼ö¿ëü
  • H2 receptor
    H2¼ö¿ëü
  • heat receptor
    ¿­¼ö¿ë±â
  • hairy skin receptor
    ÅÐÇǺμö¿ë±â
  • histamine receptor
    È÷½ºÅ¸¹Î¼ö¿ëü
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • immunoglobulin adhesion receptor
    ¸é¿ª±Û·ÎºÒ¸°ºÎÂø¼ö¿ëü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • membrane potential
    ¸·ÀüÀ§
  • reversal potential
    ¿ªÀüÀüÀ§, ¿ªÀüÀü¾Ð
  • transmembrane potential
    ¸·ÀüÀ§, ¸·Àü¾Ð
  • potential surface
    ÀüÀ§¸é
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • cold receptor
    ³Ã°¢¼ö¿ëü
  • complement receptor
    µµ¿òü¼ö¿ëü, º¸Ã¼¼ö¿ëü
  • corpuscular receptor
    ¼Òü¼ö¿ëü
  • receptor cell
    ¼ö¿ëü¼¼Æ÷
  • distance receptor
    (¢¡teleceptor) ¿ø°Ý¼ö¿ëü
  • dominant receptor
    ¿ì¼º¼ö¿ëü
  • electromagnetic receptor
    ÀüÀÚ±â¼ö¿ëü
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò
  • free receptor
    À¯¸®¼ö¿ëü
  • gustatory receptor
    ¹Ì°¢¼ö¿ëü
  • receptor gradient
    ¼ö¿ë´Ü¹é±â¿ï±â, ¼ö¿ë´Ü¹é°æ»ç
  • hairy skin receptor
    ÅÐÇǺμö¿ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • action potential
    Ȱµ¿ÀüÀ§(¡­ï³êÈ), Ȱµ¿Àü¾Ð(¡­ï³äâ)
  • alternating potential
    ±³·ù ÀüÀ§
  • generator potential
    ±âµ¿ÀüÀ§(ÑÃÔÑï³êÈ).
  • giant potential
    °Å´ëÀüÀ§(ËÝÓÞï³êÈ).
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • injury potential
    ¼Õ»ó(áßß¿)ÀüÀ§(ï³êÈ).
  • phase boundary potential
    »ó°èÀüÀ§(ßÓÍ£ ï³êÈ).
  • plateau potential
    °í¿øÀüÀ§.
  • polarizing potential
    ºÐ±ØÀü¾Ð(¡­ï³äâ).
  • positive after potential
    ¾ç¼ºÈÄÀüÀ§(åÕàõý­ï³êÈ).
  • postsynaptic potential
    ½Ã³³½ºÈÄÀü¾Ð.
  • potential
    ˟ˤ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • early eruption
    Á¶±âÃâÀº(ðÄÑ¢õóó»).
  • early fetal death
    Á¶±âžƻç¸Á.
  • early gastric cancer
    Á¶±âÀ§¾Ï.
  • early gestation
    ÀÓ½ÅÃʱâ.
  • early infantile autism
    Á¶±âÀ¯¾ÆÀÚÆóÁõ, Á¶±â¼Ò¾ÆÀÚÆóÁõ(¡­á³ä®í»øÍñø).
  • early infantile autism
    Á¶±âÀ¯¾ÆÀÚÆóÁõ(º´)(¡­í»øÍñø).
  • early labeled fraction
    Á¶±âÇ¥ÁöºÐȹ(¡­øöãÛÝÂüñ).
  • early leprosy
    Á¶±â³ª(º´).
  • early mRNA
    ÃʱâÃâÇö mRNA
  • early neonatal mortality rate
    ½Å»ý¾Æ»ç¸Á·ü(ËàË×ËâË×ËÎËô).
  • early neonatal mortality rate
    ½Å»ý¾Æ»ç¸Á·ü(ãæßæä®ÞÝØÌëÒ).
  • early operation
    Á¶±â¼ö¼ú.
  • early postprandial postgastrectomy syndrome
    Á¶±â½ÄÈļº À§ÀýÁ¦ÈÄÁõÈıº.
  • early pregnancy factor(EPF)
    ÃʱâÀÓ½ÅÀÎÀÚ
  • early protein
    ÃʱâÃâÇö´Ü¹éÁú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • floating receptor model
    ºÎÀ¯ ¼ö¿ëü(Ý©ë´áôé»ô÷) ¸ðµ¨
  • glucocorticoid receptor
    ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • H1 receptor
    H1 ¼ö¿ëü(áôé»ô÷)
  • H2 receptor
    H2 ¼ö¿ëü(áôé»ô÷)
  • LDL receptor
    LDL ¼ö¿ëü(áôé»ô÷)
  • ligand-receptor internalization
    ¸®°£µå-¼ö¿ëü(áôé»ô÷) ³»ÀÔ(Ò®ìý)
  • mineralocorticoid receptor
    ±¤Áú(ÎÎòõ) ÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • mobile receptor model
    À̵¿¼ö¿ëü(ì¹ÔÑáôé»ô÷) ¸ðµ¨
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü(áôéÄô÷)
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü(â¥é»ô÷)
  • opiate receptor
    ¾ÆÆíÁ¦(ð¥) ¼ö¿ëü(áôé»ô÷)
  • opioid receptor
    ¾ÆÆí°è(ͧ) ¾à¹°¼ö¿ëü(å·Úªáôé»ô÷)
  • receptor
    ¼ö¿ëü(áôé»ô÷)
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±«È¿¼Ò(áôé»ô÷÷òÎÕý£áÈ)
  • receptor down regulation
    ¼ö¿ëü ÇÏÇâ Á¶Àý(áôé»ô÷ù»ú¾ðàï½)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
RAR rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
ESP early systolic paradox; echo spacing; effective sensory projection; effective systolic pressure; end...
mEAD monophasic action potential early afterdepolarization
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EA Early Antigen
EBF Early B cell factor
ECC Early Childhood Caries
E.G.C. Early Gastric Cancer
Egr Early Growth Response
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • early primary closure
    Á¶±â 1Â÷ ºÀÇÕ
  • early sharp pain
    ÃʱâÀÇ ¿¹¸®ÇÑ ÅëÁõ, ÃʱâÀÇ ¿¹¸®ÇÑ µ¿Åë
    Á¶Á÷ÀÇ ¼Õ»ó ½Ã¿¡ ¿©·¯ ½Å°æ¼¶À¯Áß A¥ä¼¶À¯°¡ ¸ÕÀú ½Å°æÀü´ÞÀ» ÇàÇϴµ¥ ÀÌ´Â ºü¸£°í ³¯Ä«·Î¿î ÅëÁõÀ» º¸ÀδÙ. ÀÌÈÄ¿¡ ´À¸®°í ¹¬Á÷ÇÑ ÅëÁõÀÌ ¿À´Â C ¼¶À¯°¡ Àü´ÞÀ» ÇàÇÑ´Ù.
  • early symptom
    Ãʱâ Áõ»ó
  • early treatment
    Á¶±â Ä¡·á
    Ä¡·á È¿°ú¸¦ ¿Ã¸®±â ½¬¿î ½Ã±â¿¡ Ä¡·á¸¦ ÇàÇÏ´Â °Í.
  • involving early overgrowth
    Á¶±â °úÀ× ¹ßÀ°°ú °ü·ÃµÈ
  • absolute potential
    Àý´ë Àü¾Ð, Àý´ë ÀüÀ§
  • action potential
    Ȱµ¿ ÀüÀ§, Ȱµ¿ Àü¾Ð
    ±ÙÀ°¼¼Æ÷ ¶Ç´Â ½Å°æ¼¼Æ÷°¡ ÈïºÐÇÒ ¶§ »ý±â´Â Àü±âÀû Ȱ¼ºÀ¸·Î¼­, Àü±âÀû, È­ÇÐÀû, ±â°èÀû ÀÚ±Ø ¹× ¿Âµµº¯È­ µî¿¡ ÀÇÇÏ¿© »ý±ä´Ù°í »ý°¢Çϰí ÀÖ´Ù.
  • adaptive potential
    ÀûÀÀ ÀáÀç·Â
    µ¿ÀǾî=ada
  • after-potential
    ÈÄ ÀüÀ§ Çö»ó
    ½ºÆÄÀÌÅ© ÀüÀ§ µÚ¿¡ º¼ ¼ö ÀÖ´Â ÀüÀ§ º¯µ¿ÀÌ´Ù. À½¼º ÈÄ ÀüÀ§¿Í ¾ç¼º ÈÄ ÀüÀ§·Î ³ª´¶´Ù. ÀüÀÚ´Â ¿ªÄ¡ÀÇ »ó½Â, ÈÄÀÚ´Â Çϰ­À» ÀÏÀ¸Å²´Ù.
  • body surface potential mapping
    üǥ¸é ÀüÀ§µµ
  • chemical potential
    È­ÇÐ ÀüÀ§, È­ÇÐ Æ÷ÅÙ¼³
  • compound action potential
    º¹ÇÕ È°µ¿ Àü¾Ð
  • contact potential difference
    Á¢ÃË ÀüÀ§Â÷
  • disability potential
    Àå¾ÖÀÇ ÀáÀ缺
  • dorsal root potential
    Èı٠Àü¾Ð
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
early neonatal death Death of a liveborn infant occurring less than 7 completed days (168 hours) from the time of birth, late neonatal death, death of a liveborn infant occurring after 7 completed days of age but before 28 completed days.
(05 Mar 2000)
early-phase response Prompt onset of symptoms following an antigenic stimulus.
(05 Mar 2000)
early posttraumatic epilepsy Seizures beginning within one week after severe head injury.
(05 Mar 2000)
early reaction Local or generalised response that begins within a few minutes to about an hour after exposure to an antigen to which the individual has been sensitised.
See: skin test, wheal-and-erythema reaction.
Synonym: early reaction.
(05 Mar 2000)
early region <molecular biology> Part of a viral genome in which early genes genes that are transcribed and expressed early during infection of a cell are clustered.
(18 Nov 1997)
early seizure A seizure occurring within one week after craniocerebral trauma.
(05 Mar 2000)
early seral species <plant biology> Shrubs, such as ceanothus, and hardwoods, usually in tree form, such as red alder, bitter cherry and big leaf maple. These species start growing in natural succession soon after a disturbance (fire or logging).
(05 Dec 1998)
early stage breast cancer <oncology> Cancer is confined to the breast and has not spread to other sites in the body.
(16 Dec 1997)
early syphilis Primary, secondary, or early latent syphilis, before any tertiary manifestations have appeared.
(05 Mar 2000)
action potential <physiology> The sequential, electrochemical polarization and depolarisation that travels across the membrane of a nerve cell (neuron) in response to stimulation (touch, pain, cold, etc.)
(09 Oct 1997)
bioelectric potential Electrical potential's occurring in living organisms.
(05 Mar 2000)
biological hazard potential <radiobiology> Measure of the hazard posed by a given quantity of radioactive material in which the variation in biological effects of the various elements are accounted for.
See: integrated biological hazard potential.
(21 Mar 1998)
biotic potential <biology, ecology> The potential growth a population of living things can expect if it were living under ideal environmental circumstances.
(19 Jan 1998)
body surface potential mapping Recording of regional electrophysiological information by analysis of surface potentials to give a complete picture of the effects of the currents from the heart on the body surface. It has been applied to the diagnosis of old inferior myocardial infarction, localization of the bypass pathway in wolff-parkinson-white syndrome, recognition of ventricular hypertrophy, estimation of the size of a myocardial infarct, and the effects of different interventions designed to reduce infarct size. The limiting factor at present is the complexity of the recording and analysis, which requires 100 or more electrodes, sophisticated instrumentation, and dedicated personnel.
(12 Dec 1998)
brain potential <physiology> The electrical charge of the brain as compared to a point on the body; the potential may be steady (DC potential) or may fluctuate at specific frequencies when recorded against time, giving rise to the electroencephalogram.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Early Modern English
    ÃÊ±â ±Ù´ë ¿µ¾î
  • early
    À̸¥;ÃʱâÀÇ;ÀϵǴÂ;¸º¹°ÀÇ;¾î¸±¶§ÀÇ;°¡±î¿î Àå·¡ÀÇ(at an early date)±Ý¸í°£¿¡;¸ÓÁö ¾Ê¾Æ;ÀÏÂïÀÚ°í ÀÏÂï ÀϾ´Ù(keep early hours);ÀÏÂï;À̸¥ ¶§¿¡;Ãʱ⿡
  • early Victorian
    ºòÅ丮¾Æ ¿ÕÁ¶ ÃʱâÀÇ(»ç¶÷(ÀÛ°¡));±¸½ÄÀÇ(»ç¶÷)
  • early bird
    (±¸)À̸¥ ¾ÆÄ§ÀÇ;ÀÏÂï ¿À´Â »ç¶÷À» À§ÇÑ
  • early bird
    ÀÏÂï ÀϾ´Â »ç¶÷;Á¤ÇÑ ½Ã°¢º¸´Ù ÀÏÂï ¿À´Â »ç¶÷
  • early closing
    °³Á¡ ½Ã°£ ´ÜÃà(ÀÏ)
  • early door
    Ưº° ÃâÀÔ±¸(Ưº° ¿ä±ÝÀ¸·Î Á¤°¢º¸´Ù »¡¸® ÀÔÀå½ÃŰ´Â ¹®)
  • early leaver
    (¿µ)(Çб³ÀÇ)Áßµµ ÅðÇÐÀÚ;³«¿ÀÀÚ
  • early warning
    (¹æ°ø µîÀÇ)Á¶±â °æº¸
  • early-to-bedder
    ÀÏÂï ÀÚ´Â »ç¶÷
  • early-warning radar
    ÇÙ°ø°Ý¿¡ ´ëÇÑ Á¶±â °æº¸ ·¹ÀÌ´õ
  • early-warning system
    (±º)(ÇÙ°ø°Ý¿¡ ´ëÇÑ)Á¶±â °æº¸ Á¶Á÷
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á